RenalSense today announced that it won CE Mark approval from its Clarity RMS system that monitors urine flow in critical care and perioperative settings.
The Clarity RMS system continuously measures urine flow and automatically transmits real-time data and notifications of fluctuations to help with rapid intervention while monitoring treatment efficacy and fluid management.
Jerusalem-based RenalSense partnered with Fresenius Medical Care to distribute the technology in Europe following the CE Mark approval.
“The CE Mark is a significant milestone for RenalSense, enabling our distribution partner, Fresenius Medical Care, to launch sales to European medical centers, where urine output will now be able to be monitored electronically in real-time, as is the standard practice for other vital signs in the OR and ICU,” CEO Avi Kleiman said in a press release.
